IT0005590150 20240621 30000 (I10105) News

Form 8-K - Current report

Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028

$118.1 million, or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Omeros Corporation Reports First Quarter 2024 Financial Results

– Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering...

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31...

Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress

-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation -- Omeros...

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

– Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering...

Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31...

Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 8-K - Current report

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust

– Expands DRI royalty deal on U.S. net sales of OMIDRIA – – Expanded deal brings Omeros $115 million upfront payment and opportunity for...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form 4 - Statement of changes in beneficial ownership of securities